Finance

Beta
Lists
EVMN:NYSE
Evommune Inc
$24.13
+2.64%
(+0.62) 1D
Jun 25, 4:00:06 PM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for EVMN...
Open
$23.42
High
$24.72
Low
$22.92
Mkt. cap
865.88M
Avg. vol.
471.09K
Volume
323.27K
52-wk high
$33.20
52-wk low
$13.88
EPS
-$2.45
Shares outstanding
36.02M
No. of employees
48
Open
$23.42
High
$24.72
Low
$22.92
Mkt. cap
865.88M
Avg. vol.
471.09K
Volume
323.27K
52-wk high
$33.20
52-wk low
$13.88
EPS
-$2.45
Shares outstanding
36.02M
No. of employees
48
News stories
From sources across the web
About Evommune Inc
CEO-
Employees48
Founded2020
HeadquartersPalo Alto, California, United States
SectorBiotechnology
Websiteevommune.com
Analyst ratings
Based on 6 analysts giving stock ratings to EVMN in the past 3 months
Strong buy
Buy
6
Hold
0
Sell
0
12-month forecast
Based on 6 Wall Street analysts offering 12 month price targets for EVMN in the last 3 months.
Highest
Current $24.13
$55.00 (+127.93%)
Average
$51.80 (+114.67%)
Lowest
$50.00 (+107.21%)
Analyst
Recommendation
Action
Price target
Projected
Date
Judah Frommer
Morgan Stanley
Buy
Maintained
$55.00
+127.9%
06/12/2026
Matt Phipps
William Blair
Buy
Maintained
-
-
06/10/2026
Mitchell Kapoor
H.C. Wainwright
Buy
Reiterated
$50.00
+107.2%
05/26/2026
Kostas Biliouris
Oppenheimer
Buy
Reiterated
$50.00
+107.2%
05/15/2026
Brian Abrahams
RBC Capital
Buy
Maintained
$50.00
+107.2%
05/12/2026
Alex Thompson CFA
Stifel Nicolaus
Buy
Initiated
$54.00
+123.8%
05/01/2026
Kaveri Pohlman
Clear Street
Buy
Initiated
$53.00
+119.6%
03/17/2026
Thomas Smith
Leerink Partners
Buy
Reiterated
$52.00
+115.5%
03/06/2026
Gavin Clark-Gartner
Evercore ISI
Buy
Maintained
$55.00
+127.9%
02/10/2026
Last report
May 7, 2026
Fiscal period
Q1 2026
EPS / Est. (USD)
-$0.64 / -$0.87
+26.58%beat
Revenue / Est. (USD)
- / 619.00K
Fiscal Q1 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Revenue
-
10.00M
-
-
Cost of goods sold
-
-
-
-
Cost of revenue
-
-
-
-
Research and development expenses
19.64M
19.64M
20.40M
17.32M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
3.36M
3.69M
9.31M
6.64M
Operating expense
22.99M
23.33M
29.72M
23.95M
Total operating expenses
22.99M
23.33M
29.72M
23.95M
Operating income
-22.99M
-13.33M
-29.72M
-23.95M
Other non operating income
9.03M
-9.00K
-
-4.00K
EBT including unusual items
-13.56M
-12.48M
-28.27M
-21.67M
EBT excluding unusual items
-13.56M
-12.48M
-28.27M
-21.67M
Income tax expense
-
-
-
-
Effective tax rate
-
-
-
-
Other operating expenses
-
-
-
-
Net income
-13.56M
-12.48M
-28.27M
-21.67M
Net profit margin
-
-124.75%
-
-
Earnings per share
-
-8.07
-1.43
-0.64
Interest and investment income
404.00K
862.00K
1.44M
2.28M
Interest expense
-3.00K
-
-
-
Net interest expenses
401.00K
862.00K
1.44M
2.28M
Depreciation and amortization charges
-
-
-
-
EBITDA
-22.62M
-13.02M
-29.39M
-23.60M
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

What's on your mind?
Give me an overview of EVMN
Explore what’s possible
Deep Search
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer